People using Control-IQ technology reported outcomes reflecting high device satisfaction and reduced diabetes impact. Factors contributing to high trust in the system included sensor accuracy, improved diabetes control, reduction in extreme blood glucose levels, and improved sleep quality. In addition, participants reported improved quality of life, ease of use, and efficient connectivity to the continuous glucose monitoring system as being valuable features of the system.
67% of people using Control-IQ technology have less aggressive settings than the AACE guidelines (100/TDI). The Correction Factor is a unique parameter with CIQ, that affects user boluses, the autocorrection bolus, and the intensity of basal modulation. For Control-IQ users, strengthening the Correction Factor may improve TIR without necessarily impacting hypoglycaemia. Both C:I ratio and basal rate changes can be considered as well, although may predict more hypoglycaemia.
People who used Control IQ technology improved their TIR and also had significant reductions in mean glucose, hyperglycaemia metrics, hypoglycaemic metrics, and HbA1c. At baseline, the amount of hypoglycaemia was low, but a reduction in time <3.9mmol/L and time <3.1mmol/L were observed with Control-IQ.
Control IQ use increased TIR from 63.6% to 73.6%, which is equivalent to 2.4 hours per day, seen across all age groups. These results were evident after the first two weeks and was sustained throughout the entire year. A notable improvement was also seen overnight, with a median time in range exceeding 90% between 04:00 and 07:00, demonstrating the effectiveness of the Sleep Activity feature in Control-IQ technology. TBR remained consistent at ∼1%.
Now you can get all the latest news and updates of our products, events and resources right into your inbox.
